Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
about
IL-23 promotes tumour incidence and growthNormalization of the vasculature for treatment of cancer and other diseases.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionAccumulation of CCR4⁺CTLA-4 FOXP3⁺CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cellsAAV2-mediated in vivo immune gene therapy of solid tumours.Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDSCD4 cells can be more efficient at tumor rejection than CD8 cellsThe graft-versus-lymphoma effect: clinical review and future opportunities.T cell-mediated immunotherapy of metastases: state of the art in 2005.Stimulation of autoimmunity by toll-like receptor ligands.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.Remodeling of tumor stroma and response to therapy.Targeted regulation of a lymphocyte-endothelial-interleukin-6 axis by thermal stress.Tissue vaccines for cancer.Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer.Regulatory T cells in gastrointestinal tumors.MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response.Renal cell carcinoma: molecular characterization and evolving treatment paradigms.Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells.Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells.The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.Are epsins a therapeutic target for tumor angiogenesis?Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.Improving immune-vascular crosstalk for cancer immunotherapy.Making and circumventing tolerance to cancer.Immunotherapy of malignant melanoma – Basic principles and novel therapeutic approaches
P2860
Q28239522-CFF0299C-75D7-4DF6-A591-E9F068D34A7BQ30471456-CFF7AC60-5B46-40B0-A5E1-07645A420F77Q33931434-881C536C-01D7-434E-91C8-CDDD3BB84AC4Q34154623-BD62FC9D-BC25-4670-AD8B-870E1DA68B71Q34468330-032F5264-8A8A-4BE8-9F3D-BF06DDEFFF5AQ35680814-5F8861F6-6AD4-413E-8D06-E2E6020D96C8Q35784621-B3CEAE73-1E4D-4D12-B2CB-80E7B7F2B084Q35839925-C90C6495-F148-4F83-B753-D11423C32E61Q36128232-8BB1DE8B-0603-4068-AA0C-8C261078B7F7Q36210864-B5242EB0-0DF4-4D89-A446-4E3DDC1DCFEFQ36292615-ACFF8A6D-6E5D-4626-8999-8C0AD1BF730CQ36471827-43FA738B-A6B4-4A2E-ABDF-497E7F2A680DQ36853440-56FE3C74-0E4E-4B38-84AF-7A2DAFD43687Q37016995-82194B1D-D50F-4795-93CE-379972C2B202Q37063499-3AB6D162-5CC6-4C11-A5B3-64161F96F8D0Q37123446-14ED2AF8-3CAA-40A7-B3A4-CCC769280C20Q37394717-A74D145D-3336-4708-8E8F-01D3B0F6EC7DQ37903852-1A622508-BD18-4A9D-942A-5B1EEEA8CAD0Q38098095-58AC0D7B-579D-4194-8F02-609F6D822081Q39157961-075645A6-3F8A-4620-87E0-642C61410F39Q39904256-51ADBDCC-CD86-4674-8C52-1EA5A47DB332Q39934421-75271341-630F-450F-A35E-AF0010FF26ADQ39941375-2C0306EC-FDC2-4CB7-9265-BA13D0CA61B6Q40088629-E91CE13F-B5C0-4072-B4D3-7B9BBAFCC4E7Q40580231-DBF7FDB2-8FD6-41A2-9535-88E3E133A3CEQ41844357-FE8EEE01-9746-4D8F-A3BD-282C990DFE41Q43108657-68246E92-11AA-4BB7-97F7-0D5815BFBD23Q50051034-3D7E6F3E-1877-4294-8C79-7D9F7CA93931Q52909563-219C91AC-51AE-4068-92E5-6B0028641FCBQ57732968-F082607D-0740-4DD7-9F30-BD6E0910CB07
P2860
Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
@ast
Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
@en
type
label
Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
@ast
Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
@en
prefLabel
Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
@ast
Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
@en
P356
P1476
Mini-review: overcoming tumor-intrinsic resistance to immune effector function
@en
P2093
Bernd Arnold
Günter J Hämmerling
P304
P356
10.1002/EJI.200425474
P407
P50
P577
2004-10-01T00:00:00Z